Thriving Aspen seeks more expansion, and is eyeing women’s health
03 July 2017 - 18:06
Aspen Pharmacare is expecting further acquisitions in the next 12 months as strong revenue and lower capital expenditure restore its firepower, after the purchase of two anaesthetics portfolios in 2016. The potential deals will probably be made in the South African company’s existing pharmaceutical markets, with women’s health a possible area of expansion, CEO Stephen Saad said in an interview at Aspen’s headquarters in Durban, on Friday. The drugmaker, which has operations in more than 150 countries, will focus on emerging markets, rather than developed ones, the billionaire said.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.